Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

A fresh wave of layoffs jolted the Bay Area during March with several rounds of cutbacks that erased well over 600 jobs.

By Sabrina Valle NEW YORK (Reuters) -Large deals involving pharmaceutical and biotech companies are stalling as executives ...

There’s been no shortage of either in recent weeks. Plunging valuations across the biotech sector were thrust into the ...

Australian money managers Regal Partners Ltd. and Pengana Capital Group Ltd. are facing increased scrutiny from investors ...

A Durham biotechnology company has seen its stock price plummet over the past few days amid a stock offering and a media ...

Acknowledging the crucial role of start-ups in propelling India's biotech sector, Dr. Singh called for stronger handholding ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

Biotech is an area that may offer your portfolio growth today and earnings stability tomorrow. The idea is a biotech stock ...

Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model. In the Thursday late trading session, the ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Portage Biotech (PRTG) presented new preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor. The new data demonstrate both ...